Regen BioPharma Inc Cash Flow Statement
RGBP|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$383,591
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Regen BioPharma Inc used $383,591 in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -86.67 (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.3M | -$668.3K | $1.2M | $2.4M | -$6.8M | $3.4M | -$2.6M | -$4.7M | -$5.8M | -$7.8M | -$11.2M |
| Operating Cash Flow | -$383.6K | -$751.5K | -$173.9K | -$606.9K | -$1.1M | $18.6K | -$481.8K | -$1.6M | -$1.9M | -$1.7M | -$1.2M |